Harmony Biosciences Holdings, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $HRMY in the last 7 days.
Budur Kumar (CHIEF MEDICAL OFFICER) sold 38,452 shares of Harmony Biosciences Holdings, Inc. (HRMY) at an average of $43.05 ($43.00–$43.05, $1.66M total) across 3 trades over 2026-09-16 to 2026-09-18 under a Rule 10b5-1 trading plan.
Kumar Budur, Chief Medical Officer of Harmony Biosciences Hldgs (HRMY), exercised options for 22,954 shares at $30.49 each, totaling $262,978. HRMY shares are down 1.57%, trading at $41.95. The company reported 30.32% revenue growth, a 75.81% gross margin, and an EPS of 1.3. Its P/E ratio is 13.47, and its EV/EBITDA is 6.82.
Budur Kumar (CHIEF MEDICAL OFFICER) sold 33,954 shares of Harmony Biosciences Holdings, Inc. (HRMY) at an average of $42.80 ($41.98–$43.10, $1.45M total) across 4 trades over 2026-09-04 to 2026-09-08 under a Rule 10b5-1 trading plan.
Recent HRMY coverage spans financial news, insider activity and earnings.
In the last 30 days, HRMY insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($2.9M). The most active reporter was Budur Kumar, CHIEF MEDICAL OFFICER, with 6 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider sale may signal limited confidence, potentially exerting slight downward pressure.
Small insider purchase may signal confidence but size is modest relative to market cap.
This is a routine 10b5-1 insider sale disclosure, more useful for monitoring than for signaling a fundamental change.
Regulatory acceptance reduces product launch risk and supports revenue outlook.
New coverage could boost sentiment.
AlphAI scores every news story that mentions HRMY with an AI model for sentiment and relevance, and aggregates insider trades from Harmony Biosciences Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Budur Kumar (CHIEF MEDICAL OFFICER) sold 38,452 shares of Harmony Biosciences Holdings, Inc. (HRMY) at an average of $43.05 ($43.00–$43.05, $1.66M total) across 3 trades over 2026-09-16 to 2026-09-18 under a Rule 10b5-1 trading plan.
1 min readKumar Budur, Chief Medical Officer of Harmony Biosciences Hldgs (HRMY), exercised options for 22,954 shares at $30.49 each, totaling $262,978. HRMY shares are down 1.57%, trading at $41.95. The company reported 30.32% revenue growth, a 75.81% gross margin, and an EPS of 1.3. Its P/E ratio is 13.47, and its EV/EBITDA is 6.82.
1 min readBudur Kumar (CHIEF MEDICAL OFFICER) sold 33,954 shares of Harmony Biosciences Holdings, Inc. (HRMY) at an average of $42.80 ($41.98–$43.10, $1.45M total) across 4 trades over 2026-09-04 to 2026-09-08 under a Rule 10b5-1 trading plan.
2 min readHarmony Biosciences (HRMY) stock rose 12.1% since last earnings. The company expects multiple clinical trial data in 2026-2027, including for pitolisant GR and epilepsy treatments. HRMY reaffirmed 2026 revenue guidance of $1B-$1.04B, with Q2 revenues up 21% sequentially. Analysts have upwardly revised estimates, and HRMY has an aggregate VGM Score of A.
2 min readUBS upgraded SolarEdge (SEDG) to Buy with a $42 target, citing FCC benefits. Wolfe upgraded DT Midstream (DTM) to Outperform with a $145 target. Piper upgraded Neogen (NEOG) to Overweight with a $14 target. UBS upgraded Argenx (ARGX) to Buy with a $1,400 target. National Bank upgraded Scotiabank (BNS) to Outperform with a C$142 target. JPMorgan and BofA downgraded Intuit (INTU) to Neutral with a $331 target. Truist downgraded Dick's Sporting (DKS) and Nike (NKE). Wells downgraded GoDaddy (GDDY).
2 min readAnalysts initiated coverage on several companies: Needham rated Evommune (EVMN) Buy with a $28 target, Daiwa rated ACM Research (ACMR) Buy with a $136 target, Wolfe Research rated Harmony Biosciences (HRMY) Outperform with a $60 target, RBC rated Atlassian (TEAM) Outperform with a $215 target, and RBC rated JFrog (FROG) Outperform with a $118 target.
2 min readHarmony Biosciences (HRMY) told investors at Piper Sandler’s Virtual CNS Symposium that WAKIX continues to deliver record quarterly sales and funds its CNS pipeline. The company outlined pitolisant GR (PDUFA Apr 27) and pitolisant HD (top-line 2027, PDUFA 2028), plus BP-205 and EPX-100. HRMY shares closed at $38.5.
6 min readHarmony Biosciences (HRMY) reported Q2 2026 WAKIX net revenue of $261.3 million, up 30% year over year, and confirmed 2026 revenue guidance of $1.0 billion to $1.04 billion. Net income was $75.4 million ($1.28/diluted share). Cash and investments were $962.5 million as of June 30, 2026. The company also discussed BP-205 clinical data and pipeline timelines.
10 min readHarmony Biosciences (NASDAQ:HRMY) reported Q2 EPS of $1.28, above a 94-cent consensus, and sales of $261.3 million versus $248.41 million expected. WAKIX net revenue rose 30% to $261.3 million, and HRMY reiterated full-year WAKIX guidance of $1.0B to $1.04B. The company also shared Phase 1 BP-205 SAD data and plans Phase 2 studies from mid-2027.
5 min readOppenheimer cut its Harmony Biosciences (NASDAQ:HRMY) price target to $70 from $85 but kept an Outperform rating after model updates. Harmony reported Q2 2026 Wakix net sales of $261.3M (+30% YoY) and reaffirmed full-year guidance of $1.00B to $1.04B. Oppenheimer cited new Phase 1 data for BP-205 and expects further Phase 1 readouts in Q4 2026 and early 2027.
4 min read
